Fibromodulin peptide
Embodiments of the present invention provide a fibromodulin (FMOD) peptide (FMOD-P), a composition and a formulation comprising a FMOD-P, option-ally with a TGF-β isoform, or comprising FMOD with a TGF-β isoform. The present invention also provides methods of making and using the FMOD-P, composition, or formulation.
1. An isolated fibromodulin (FMOD) peptide (FMOD-P), wherein FMOD-P is a chemically modified isoform of a full length FMOD, wherein the FMOD-P consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO:24, SEQ ID NO: 26, SEQ ID NO: 28, and SEQ ID NO: 34, and wherein the chemically modified isoform is achieved by using an acid, a base, esterification, PEGylation, or alkylation with a short chain alkyl group.
2. The FMOD-P of claim 1 , wherein the isolated FMOD-P binds one TGF-β selected from the group consisting of TGF-β1, TGF-β2, and TGF-β3.
3. A composition, comprising a pharmaceutically acceptable carrier and an effective amount of any of the following ingredients:
a) an isolated FMOD-P;
b) a combination of two or more isolated FMOD-P;
c) an isolated FMOD-P or a combination of two or more isolated FMOD-P and at least one TGF-β isoform;
d) isolated FMOD and isolated FMOD-P or a combination of two or more isolated FMOD-P; and
e) any combination of (a)-(d), wherein FMOD-P is an isoform of a full length FMOD, wherein the at least one TGF-β isoform is selected from the group consisting of TGF-β1, TGF-β2, TGF-β3, and a combination thereof, wherein the isolated FMOD-P consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28, and SEQ ID NO: 34, and wherein FMOD consists of an amino acid sequence selected from the group consisting of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 10, SEQ ID NO. 11, and SEQ ID NO. 12.
4. The composition of claim 3 , wherein the isolated FMOD-P binds one TGF-β selected from the group consisting of TGF-β1, TGF-β2, and TGF-β3.
5. The composition of claim 3 , further comprising an excipient.
6. The composition of claim 5 , wherein the excipient is a pharmaceutically acceptable carrier or dermatologically acceptable carrier.
7. A formulation comprising the composition of claim 3 and an excipient, wherein the formulation is for systemic or local delivery.
8. The formulation of claim 7 , wherein the local delivery is topical delivery, transdermal delivery, intradermal delivery, micro needle delivery, delivery as a coating on medical devices, or delivery by impregnating or coating on scaffold devices, and wherein the systemic delivery is injection, oral administration, nasal delivery, or inhalation.